The US Food and Drug Administration (FDA) has approved the first oral GLP-1 receptor agonist, Rybelsus (semaglutide), to help prevent heart attack and stroke in adults with type 2 diabetes and high cardiovascular risk.
The approval marks a major expansion of Rybelsus’s role, which was first cleared in 2019 for blood sugar management. Now, based on new evidence from the SOUL trial, the drug can be prescribed to reduce major adverse cardiovascular events (MACE), a combined measure of cardiovascular death, nonfatal heart attack, or nonfatal stroke, even in patients who have not yet
Continue Reading on India Today
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.